Abstract: A flight vehicle includes a nose portion, a fuselage retaining structure aft of the nose portion, and an axial motor for expelling axial thrust along a longitudinal axis of the flight vehicle. Radial motors are coupled to the retaining structure and axisymmetrically arranged about the axial motor. Each radial motor is configured to expel radial thrust radially outwardly in respect to the flight vehicle. Roll thrusters are operatively coupled with the radial motors and coupled to the fuselage retaining structure. The roll thrusters are configured to provide a roll moment of the flight vehicle about a central longitudinal axis of the flight vehicle. Ejectors are operatively coupled to the radial motors, and a controller is operatively coupled to the radial motors and the ejectors. The controller is configured to selectively fire and selectively eject the radial motors to maintain relative centering of a center of gravity of the flight vehicle.

Abstract: A flight vehicle includes a nose portion, a fuselage retaining structure aft of the nose portion, and an axial motor for expelling axial thrust along a longitudinal axis of the flight vehicle. Radial motors are coupled to the retaining structure and axisymmetrically arranged about the axial motor. Each radial motor is configured to expel radial thrust radially outwardly in respect to the flight vehicle. Roll thrusters are operatively coupled with the radial motors and coupled to the fuselage retaining structure. The roll thrusters are configured to provide a roll moment of the flight vehicle about a central longitudinal axis of the flight vehicle. Ejectors are operatively coupled to the radial motors, and a controller is operatively coupled to the radial motors and the ejectors. The controller is configured to selectively fire and selectively eject the radial motors to maintain relative centering of a center of gravity of the flight vehicle.

Abstract: Human TAOJIK genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of TAOJIK are provided.

Abstract: Embodiments of the present invention include the steps of (i) defining a first resource containing information objects defining a set of users; (ii) discovering said information objects based on said first resource definition; (iii) associating each of said information objects with a user from said set of users and said first resource. Embodiments of the present invention can include delegation of discovery tasks to allow additional resources to be defined.

Abstract: RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.

Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.

Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.

Abstract: RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.

Abstract: Human TAOJIK genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of TAOJIK are provided.

Abstract: Embodiments of the present invention include the steps of (i) defining a first resource containing information objects defining a set of users; (ii) discovering said information objects based on said first resource definition; (iii) associating each of said information objects with a user from said set of users and said first resource. Embodiments of the present invention can include delegation of discovery tasks to allow additional resources to be defined.